Study #2024-0436
A phase 1b/2 open-label study of APVO436 in combination with Venetoclax and Azacitidine in patients with newly diagnosed acute myeloid leukemia (AML).
MD Anderson Study Status
Not Accepting
Treatment Agent
APVO436, Venetoclax, Azacitidine
Description
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia (AML)
Study phase:
Phase I
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?